Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS

Table 4

Deregulated proteins in prostate cancer identified with 2D-DIGE and MS.

Spot		Acc. no.	Protein name	Ratio Tf versus Tu	value (-test) Tf versus Tu	value (-test) Tf versus Tu
Down 01		P22626	Heterogeneous nuclear ribonucleoproteins A2/B1	−21.8	0.043	0.035
Down 05		P17661	Desmin	−15.7	0.156	0.024
Down 06		P17661	Desmin	−9.1	0.085	0.009
Down 04		P17661	Desmin	−3.8	0.037	0.012
Down 09		P09493	Tropomyosin alpha-1 chain	−2.9	0.035	0.042
Down 10		P09493	Tropomyosin alpha-1 chain	−2.9	0.009	0.020
Down 08		P09493	Tropomyosin alpha-1 chain	−2.8	0.010	0.019
Down 07		P12277	Creatine kinase B-type	−2.7	0.045	0.009
Down 11		Q05682	Caldesmon	−2.2	0.115	0.026
Down 02		P08670	Vimentin	−1.7	0.053	0.024
Down 03		P17661	Desmin	−1.6	0.039	0.110
Up 01		COEA1	Collagen alpha-1(XIV) chain	2.4	0.104	0.042
Up 03	Mix	ANXA5	Annexin A5	3.7	0.038	0.033
		A1BG	Alpha-1B-glycoprotein	3.7	0.038	0.033
		P04217	Alpha-1B-glycoprotein	3.7	0.038	0.033
Up 02		TCPA	T-complex protein 1 subunit alpha	46.7	0.405	0.049

2D-DIGE: two-dimensional differences in gel electrophoresis; MS: mass spectrometry; Acc. no.: accession number; Tf: tumor free; Tu: tumor; -test: two-sided Mann-Whitney -test; ratio: division of the mean; mean: normalized spot volume.